



Healthcare Weekly News and Deals –June 29th, 2026

- 1. The Doctors Company, the nation's largest physician-owned medical malpractice insurer and parent of TDC Group, has completed its \$1.3 billion all-cash acquisition of specialty insurer ProAssurance Corporation (NYSE: PRA) at \$25.00 per share, creating a combined platform protecting more than 200,000 healthcare professionals nationwide.**

Napa, California-based The Doctors Company finalized its \$1.3 billion buyout of ProAssurance (NYSE: PRA), acquiring all outstanding shares at \$25.00 per share in cash — a transaction that ProAssurance shareholders had approved in June 2025. With the deal closed, PRA's common stock has been delisted from the NYSE and deregistered with the SEC. The combined entity, operating under TDC Group, now holds \$12 billion in assets and more than \$2.5 billion in direct written premium, pairing The Doctors Company's medical malpractice franchise with ProAssurance's specialty lines spanning medical liability, medical technology and life sciences products liability, and workers' compensation. ProAssurance will operate as a wholly owned subsidiary while an optimal structural review is conducted. ([Link](#))
- 2. Merck KGaA Agrees to Acquire Bio-Techne Corporation (NASDAQ: TECH) for \$11.3 Billion in Cash at \$73 Per Share — a 36% Premium to the One-Month VWAP — in Merck KGaA's Largest Acquisition Since the \$17 Billion Sigma-Aldrich Deal in 2014**

Merck KGaA, Darmstadt, Germany, entered into a definitive agreement on June 25, 2026 to acquire Minneapolis-based Bio-Techne (Nasdaq: TECH), a global provider of life science tools including 6,000 recombinant proteins, 425,000 antibodies, ProteinSimple analytical instruments, and RNAscope spatial biology technologies, for \$73 per share in cash — a total enterprise value of approximately \$11.3 billion. The transaction will be funded through existing cash and new debt while preserving an investment-grade rating, with Merck KGaA expecting immediate EBITDA accretion and approximately €140 million in annual cost synergies by year three; the deal is expected to close in late 2026 or early 2027 pending Bio-Techne shareholder and regulatory approvals. ([Link](#))
- 3. PsychPlus, a Houston-based psychiatric and therapeutic care provider, has acquired multinational digital mental health platform Koa Health to form what the companies describe as the world's largest technology-enabled mental health company.**

PsychPlus completed its acquisition of Koa Health in an all-strategic transaction whose value was not disclosed, positioning the combined platform to serve more than 6 million patients across the US, Europe, Australia, and Asia-Pacific. The deal pairs PsychPlus's proprietary clinical technology network — scaled to over 200 US locations in five years — with Koa Health's digital-first delivery model, 56 patents, and 23 peer-reviewed studies. Led by CEO Dr. Faisal Tai, PsychPlus is investing to build an integrated, multi-channel care continuum; Koa Health founder Dr. Oliver Harrison joins as President. The combination targets faster patient access and a scalable global mental-health blueprint. ([Link](#))

Healthcare Weekly News and Deals – June 29th, 2026

4. [Strata Critical Medical, Inc. \(Nasdaq: SRTA\) has acquired the Heart and Lung Transplant National Recovery Program \(HLT-NRP\) for \\$21.5 million to expand its national organ recovery platform.](#)

Strata Critical Medical (Nasdaq: SRTA) completed its purchase of HLT-NRP at a mid-single-digit multiple of pre-synergy Adjusted EBITDA, structured as roughly 80% cash and 20% stock subject to a multi-year lockup tied to the seller's continued involvement. HLT-NRP is expected to generate approximately \$10.0 million in revenue and \$3.1 million in Adjusted EBITDA for full-year 2026. Co-CEOs Will Heyburn and Melissa Tomkiel framed the deal as adding clinical depth and geographic reach in Florida and California, deepening its fastest-growing Transplant Clinical line. CFO Mat Schneider emphasized the acquisition fits Strata's capital allocation framework, expecting growth and operational synergies to lower the effective purchase price over time. ([Link](#))

5. [AMR Clinical Acquires ClinOhio Research Services, Adding a Columbus, Ohio Multi-Therapeutic Clinical Research Site Specializing in Women's Health, Dermatology, and Family Practice to Its 30+ Site National Network](#)

Knoxville, Tennessee-based AMR Clinical, a Curewell Capital-backed integrated research site organization with more than 30 U.S. locations and over 8,000 completed trials across more than 145,000 enrolled participants, announced on June 29, 2026 the acquisition of ClinOhio Research Services, a Columbus, Ohio-based multi-therapeutic clinical research facility specializing in Women's Health, Dermatology, and Family Practice. The addition expands AMR's geographic footprint into the Columbus market — home to The Ohio State University Wexner Medical Center and one of the most active clinical research ecosystems in the Midwest — and deepens its therapeutic capabilities across its Phase I–IV trial platform. AMR has grown to 30+ sites through a combination of acquisitions and organic site launches under Curewell Capital's ownership. ([Link](#))

6. [CareRite Centers has acquired the Grand Rehabilitation and Nursing at Queens from a Grand Healthcare System–linked entity \(Clearview Land LLC\) for \\$58.2 million.](#)

New Jersey–based CareRite Centers, an elder care and rehabilitation provider, deployed \$58.2 million to acquire a 179-bed facility plus an adjacent parking lot in Whitestone, Queens, in a transaction recorded June 24. The deal closed April 28 and was signed for the buyer by co-founder and principal Mark Friedman. The seller, Clearview Land LLC, appears tied to Grand Healthcare System CEO Jeremy Strauss, whose New York network spans roughly 12 skilled nursing and rehab centers. The purchase price sits far above the property's 2022 city-assessed market value of \$8.1 million, marking a substantial premium as CareRite expands its regional footprint beyond its existing Brooklyn and Manhattan facilities. ([Link](#))

7. [TELEO Capital Management has acquired pharmaceutical manufacturing intelligence platform SmartFactory Rx — now rebranded Modersys — from semiconductor-equipment maker Applied Materials, Inc. \(NASDAQ: AMAT\) in a corporate carve-out.](#)

Boise-based private equity firm TELEO Capital Management acquired Modersys (formerly SmartFactory Rx) from Applied Materials, Inc. (NASDAQ: AMAT) for an undisclosed sum, executing the carve-out strategy central to its lower-middle-market playbook. TELEO, which targets technology, software, and healthcare IT, will operate Modersys as an independent company to accelerate AI-driven product innovation for biopharma and life-sciences manufacturers. ([Link](#))

Healthcare Weekly News and Deals – June 29th, 2026

8. Incline Equity Partners has partnered with West Physics to expand its medical and health physics testing platform.

Pittsburgh-based private equity firm Incline Equity Partners, which targets the middle market with enterprise values of \$25–\$750 million, backed Atlanta-headquartered West Physics, a market leader in accreditation and testing services for MRI, CT and X-ray imaging equipment. Financial terms were not disclosed. Managing Director Nic Meiring signaled the investment thesis: pursuing expansion into adjacent service offerings and new geographies both organically and through strategic M&A within a highly fragmented industry. Founder and CEO Dr. Geoff West will continue leading the company, planning to accelerate organic growth by investing in the services support structure, in-house residency program and broader physicist network. ([Link](#))

9. Chicago Pacific Founders has made a strategic growth investment in Attune, the Chicago-based Agentic Engagement Platform for Healthcare, to scale AI-driven patient coordination across value-based care.

Healthcare-focused private equity firm and operator Chicago Pacific Founders (CPF) made an undisclosed strategic growth investment in Attune, an AI-powered patient-engagement platform. CPF — which manages more than 3 million lives across its value-based care network and invests exclusively in value-based care, healthcare services, and tech-enabled businesses — is deploying capital as an operator to embed Attune across its delivery models. The investment, framed by Co-Founder and Managing Partner Vance Vanier and Attune CEO Matt Coughlin, targets an estimated \$430–480 billion in annual US care-coordination waste. Attune has outperformed human advocate teams, exceeding one Medicaid health-risk-assessment target by 40% within three weeks of going live. ([Link](#))

10. Hunterdon Health and Hackensack Meridian Health have signed a letter of intent to pursue a proposed merger of the two New Jersey nonprofit health systems.

Flemington-based Hunterdon Health and Edison-based Hackensack Meridian Health signed a nonbinding letter of intent June 22 after both boards of trustees voted to advance merger exploration. The letter of intent is nonbinding and does not represent a final deal, with no immediate changes to patient care, staffing or compensation. As a nonprofit combination, no purchase price applies; the strategic rationale centers on pooling resources, technology and expertise to expand services, invest in clinical research, and compete against larger, better-resourced systems. Leaders Patrick Gavin and Robert Garrett cited mission alignment and patient-centered innovation as both parties work toward a definitive agreement. ([Link](#))

11. DermDox Group has acquired Modern Aesthetics Plastic Surgery, expanding its dermatology, aesthetics and specialty healthcare platform.

DermDox Group, a growing platform focused on dermatology, aesthetics and specialty healthcare services, completed a strategic transaction acquiring Modern Aesthetics Plastic Surgery. The deal reflects sustained strategic-buyer and investor demand for high-quality assets in the aesthetics and elective healthcare sectors, where consolidation continues across physician practices, med spas, plastic surgery and dermatology. The acquisition expands DermDox's capabilities within the aesthetic and surgical services market while providing Modern Aesthetics with additional resources to support future growth and patient care initiatives. ([Link](#))

Healthcare Weekly News and Deals – June 29th, 2026

12. New York-based investment group Black Pearl Equities has entered into a definitive agreement to acquire all outstanding shares of Selectis Health, Inc. (OTCQB: GBCS), a Denver-based skilled nursing and senior living operator, for \$5.75 per share in cash in a transaction valued at an implied premium to market.

Brooklyn, New York-based Black Pearl Equities has agreed to acquire Selectis Health (OTCQB: GBCS) through a cash tender offer at \$5.75 per share — a deal unanimously approved by Selectis's Board of Directors as fair and in the best interests of stockholders. The transaction, structured as a tender offer followed by a short-form merger under the Utah Revised Business Corporation Act, requires valid tender of at least 70% of outstanding shares and carries no financing contingency. The deal is expected to close in Q3 2026. Selectis currently operates eight skilled nursing, assisted living, and independent living properties across Arkansas and Oklahoma, serving Medicare, Medicaid, and private-pay residents. Black Pearl, a healthcare-focused investment and advisory firm, will take Selectis private as a wholly owned subsidiary. ([Link](#))

13. Standard Dental Labs Inc. has signed a letter of intent to acquire an additional dental laboratory in the Tampa Bay region.

Orlando-based dental laboratory consolidator Standard Dental Labs (OTCQB: TUTH) executed a non-binding LOI to acquire an established, undisclosed dental lab in Tampa Bay, advancing its strategy of building a regional Florida network. President and CEO James D. Brooks said the firm continues identifying high-quality labs whose owners value joining a larger organization. The LOI follows the company's acquisition of BRLIT Dental Laboratory last month and remains subject to due diligence and definitive agreements. Brooks emphasized that developing regional density creates economies of scale and long-term shareholder value, with an active acquisition pipeline across Central Florida driven by owner succession planning and consolidation pressures. ([Link](#))

14. Fortitude Mining Holdings, Inc., currently wholly owned by Digital Currency Group (DCG), has agreed to combine with HeartSciences Inc. (Nasdaq: HSCS) in an all-stock business combination to take its vertically integrated Zcash mining platform public.

Digital Currency Group, the sole stockholder of Fortitude Mining Holdings, will hold approximately 95% of the combined company on a fully diluted basis at closing, reflecting continued conviction in the venture mining business. Fortitude and HeartSciences (Nasdaq: HSCS) entered a definitive all-stock merger agreement expected to close in the second half of 2026, with the combined entity operating under the Fortitude brand and trading on Nasdaq under the ticker "TUDE," subject to approval. DCG founder and CEO Barry Silbert framed Zcash as one of the most compelling opportunities in digital assets, pairing Bitcoin-style scarcity and Proof-of-Work discipline with privacy properties. The public listing gives Fortitude capital-markets access to scale its mining platform. ([Link](#))

Venture Deals and Other

1. [GRAIL, Inc. \(Nasdaq: GRAL\) has completed a \\$110 million equity financing from Samsung entities, including Samsung C&T Corporation, to fund its growth and international expansion.](#)

GRAIL (Nasdaq: GRAL) closed a \$110 million equity investment from Samsung affiliates. The Samsung entities purchased GRAIL common stock at \$70.05 per share, representing a long-term investment supporting GRAIL's growth and international expansion. The strategic capital strengthens GRAIL's balance sheet and extends its cash runway as it pursues U.S. regulatory approval and reimbursement for its Galleri multi-cancer early detection test. GRAIL and Samsung C&T intend to collaborate to commercialize Galleri in South Korea, with potential expansion into Japan and Singapore. Samsung C&T, which has invested in Samsung Biologics, continues building its biopharmaceutical and life sciences portfolio through this milestone deal. ([Link](#))

2. [Assort Health has raised a \\$120 million Series C led by Menlo Ventures, with backing from Lightspeed Venture Partners, Felicis, First Round Capital, Chemistry, Joe Montana, Tau Ventures and Quiet Capital, reaching unicorn status.](#)

Assort Health secured \$120 million in Series C funding, hitting unicorn status, to scale its voice AI agent platform for healthcare. Menlo Ventures led the round, joined by Lightspeed Venture Partners, Felicis, First Round Capital, Chemistry, Joe Montana, Tau Ventures and Quiet Capital. Menlo partner Matt Murphy cited Assort's category leadership, strong ROI and proven specialty-care execution. The company has raised \$222 million to date and hit a \$1.2 billion valuation, with revenue jumping 20x in 15 months. Investors are betting on Assort's proprietary specialty dataset and Synapse AI model as defensible moats in a rapidly consolidating, capital-intensive market. ([Link](#))

3. [xCures has raised a \\$46 million Series B led by Innovius Capital, with participation from iGrow, GKCC and Spring Mountain Capital, to scale its clinical data structuring platform.](#)

xCures completed a \$46 million Series B financing led by Innovius Capital, with heavy participation from iGrow, GKCC, Spring Mountain Capital and existing institutional investors. The round pushes the company's total institutional funding past \$76 million to scale its Clinical Clarity Engine, which turns unstructured medical records into decision-ready data. Innovius Capital partner Stu Posluns emphasized that the future of healthcare AI depends on the accuracy, completeness and trust profile of underlying clinical data. xCures has processed more than 300 million medical records from over 550,000 healthcare locations, a defensive moat investors view as difficult for lightweight entrants to replicate. ([Link](#))

Healthcare Weekly News and Deals – June 29th, 2026

4. Prosper AI has raised a \$30 million Series A led by Andreessen Horowitz (a16z), with participation from Base10, Emergence Capital, Y Combinator and Company Ventures, to build an AI workforce for healthcare operations.

Prosper AI banked \$30 million to scale its agentic AI platform powering administrative tasks from patient scheduling to insurance verification and patient billing. Andreessen Horowitz led the Series A round, with participation from Base10 and continued support from Emergence Capital, Y Combinator and Company Ventures. a16z partner Jay Rughani cited the founders' ambition and strong competitive win rates as the conviction drivers, noting the platform's end-to-end pull-through across customers. The funding follows roughly 5x revenue growth since the September seed round; capital will expand engineering and customer teams and deepen integrations across major EHR platforms. ([Link](#))

5. Rapalogix Health Raises \$20 Million in Series A Financing to Advance Its Pipeline of Longevity-Based Skin Health Products Targeting the mTOR Pathway, a Scientifically Validated Mechanism Linked to Cellular Aging and Skin Regeneration

Carlsbad, California-based Rapalogix Health, a biotechnology company pioneering longevity-based skin health through mTOR pathway modulation, closed a \$20 million Series A to advance its proprietary product pipeline and expand commercial operations. Rapalogix is developing prescription and consumer products using rapamycin analogs targeting mTOR — a cellular pathway linked to aging, inflammation, and skin regeneration — in a category positioned at the intersection of dermatology, longevity medicine, and aesthetic health as investor and consumer interest in science-backed longevity products accelerates. ([Link](#))

6. Hera has raised a \$27 million Series A led by Bain Capital Ventures, with participation from Accel and IA Ventures, to expand its AI-powered senior care coordination platform.

Hera raised \$27 million in Series A funding led by Bain Capital Ventures, with continued participation from Accel and IA Ventures. Angel investors also participated, including the CFO of Mount Sinai. Bain Capital Ventures partner Alysaa Co praised the founding team's mix of personal conviction and technical depth honed at Headway and Palantir, viewing Hera's platform as one that learns what genuinely helps aging families rather than merely surfacing options. The capital will fund continued buildout of Hera's AI platform and expansion into California, Florida, Maryland, Pennsylvania and Massachusetts, targeting more than 25 states by year-end after reaching 95% retention across over 1,000 families. ([Link](#))

7. Pathway Labs has raised an \$8.5 million seed round led by AlleyCorp and Breyer Capital to deploy its FDA-cleared cardiology AI tool, alongside a partnership with OpenEvidence.

Pathway Labs announced an \$8.5 million seed round led by AlleyCorp and Breyer Capital to expand deployment across health systems, grow its clinical and commercial teams, and support ongoing R&D. The financing coincides with the launch of EchoNext, the first FDA-approved AI tool reading standard ECGs to flag structural heart disease. Breyer Capital's Dr. Morgan Cheatham praised the company for surfacing imperceptible diagnostic signals from widely ordered tests, while AlleyCorp's Dr. Alexi Nazem called the technology a pioneering new type of AI-enabled medicine. The capital will fund integration into real clinical workflows at national scale via the OpenEvidence platform. ([Link](#))

Healthcare Weekly News and Deals – June 29th, 2026

8. Upside has secured a \$20 million Series A led by Aquiline, with participation from Flare Capital Partners and existing investors 645 Ventures, Freestyle Capital, Triple Impact Capital and Techstars.

Upside banked a \$20 million Series A to address the U.S. housing crisis through a healthcare lens. Aquiline led the round, with participation from Flare Capital Partners and support from existing investors 645 Ventures, Freestyle Capital, Triple Impact Capital and Techstars. Aquiline partner Dante La Ruffa framed housing instability as a persistent driver of avoidable healthcare spend and pointed to strategic connectivity across health plan, payer and broker channels. The funding will be deployed simultaneously across Medicaid, Medicare Advantage and employer-sponsored markets, funding leadership hires, operational depth and continued technology investment as Upside scales its housing stability platform. ([Link](#))

9. Anodyne Nanotech Closes \$12.6 Million Series A Led by Velocity Partners VC to Advance ANN-101 — a Once-Weekly GLP-1 Transdermal Patch for Obesity Requiring No Injection or Cold Storage — into Phase I Clinical Trials

Boston-based Anodyne Nanotech closed a \$12.6 million Series A co-led by Velocity Partners VC and Evercurious VC, with major participation from Relativity Healthcare Partners, to advance ANN-101, its once-weekly GLP-1 patch for obesity, into Phase I clinical trials and scale manufacturing of its HeroPatch™ transdermal delivery platform capable of delivering multi-milligram weekly GLP-1 doses without an injection or cold storage. The financing also supports Anodyne's pipeline including an apelin/GLP-1 combination patch designed to counter lean-muscle loss — a key side effect of current GLP-1 injectable therapies. ([Link](#))

10. Ladder Health has raised a \$7 million seed round led by Nina Capital, with participation from Mairs & Power Venture Capital, South Dakota First Capital, 25madison Health, Hatteras Venture Partners, Create Health Ventures, Jumpstart Capital, White Oak Enterprises, Groove Capital and 7Rock Ventures.

Ladder Health raised \$7 million in an oversubscribed seed round led by Nina Capital to expand its virtual-first pediatric developmental care platform. Additional investors included Mairs & Power Venture Capital, South Dakota First Capital, 25madison Health, Hatteras Venture Partners, Create Health Ventures, Jumpstart Capital, White Oak Enterprises, Groove Capital and 7Rock Ventures. The diversified syndicate is backing a company addressing nationwide provider shortages and waitlists for pediatric therapy. The capital will support expansion across North Carolina, Massachusetts and Maryland, entry into additional markets, enhancement of its AI-enabled care platform, and deeper partnerships with pediatric practices and health systems. ([Link](#))